acetylcarnitine has been researched along with Lassitude in 15 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One month treatment with amantadine improved fatigue in patients with relapsing-remitting MS as evaluated by MFIS." | 9.17 | Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. ( Ledinek, AH; Rot, U; Sajko, MC, 2013) |
| "The aim of this study was to evaluate whether supplementation of acetyl-L-carnitine (ALC) to pegylated-interferon-α 2b (Peg-IFN-α 2b) and ribavirin (RBV) improves the health-related quality of life during the treatment for chronic hepatitis C, thereby decreasing the risk of treatment discontinuation." | 9.15 | The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin. ( Bella, R; Bertino, G; Bruno, CM; Chisari, G; Gargante, MP; Lupo, L; Malaguarnera, M; Motta, M; Neri, S; Pennisi, G; Vacante, M, 2011) |
| "Fatigue affects more than 60% of multiple sclerosis (MS) patients and is one of the most troublesome symptoms of the disease." | 6.78 | Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. ( Ledinek, AH; Rot, U; Sajko, MC, 2013) |
| "Ifosfamide and cisplatin cause urinary loss of carnitine, which is a fundamental molecule for energy production in mammalian cells." | 6.70 | Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. ( Baldelli, AM; Bisonni, R; Canestrari, F; Catalano, V; De Gaetano, A; Ferraro, B; Giordani, P; Graziano, F; Lai, V; Mencarini, E; Rovidati, S; Silva, R; Testa, E, 2002) |
| "Fatigue was assessed by the Functional Assessment of Cancer Therapy-Fatigue quality of life questionnaire." | 6.70 | Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. ( Baldelli, AM; Bisonni, R; Canestrari, F; Catalano, V; De Gaetano, A; Ferraro, B; Giordani, P; Graziano, F; Lai, V; Mencarini, E; Rovidati, S; Silva, R; Testa, E, 2002) |
| "Fatigue is an indispensable sense for ordering rest." | 5.31 | Brain regions involved in fatigue sensation: reduced acetylcarnitine uptake into the brain. ( Evengård, B; Hagberg, G; Iwase, M; Kanakura, Y; Kitani, T; Kuratsune, H; Långström, B; Lindh, G; Machii, T; Matsumura, K; Onoe, H; Takahashi, M; Watanabe, Y; Yamaguti, K, 2002) |
| "One month treatment with amantadine improved fatigue in patients with relapsing-remitting MS as evaluated by MFIS." | 5.17 | Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. ( Ledinek, AH; Rot, U; Sajko, MC, 2013) |
| "The aim of this study was to evaluate whether supplementation of acetyl-L-carnitine (ALC) to pegylated-interferon-α 2b (Peg-IFN-α 2b) and ribavirin (RBV) improves the health-related quality of life during the treatment for chronic hepatitis C, thereby decreasing the risk of treatment discontinuation." | 5.15 | The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin. ( Bella, R; Bertino, G; Bruno, CM; Chisari, G; Gargante, MP; Lupo, L; Malaguarnera, M; Motta, M; Neri, S; Pennisi, G; Vacante, M, 2011) |
| " In the completed study, adult patients with relapsing-remitting and secondary progressive MS were exposed to both acetyl L-carnitine 2 grams daily and amantadine 200 mg daily The effects of carnitine on fatigue are unclear." | 4.88 | Carnitine for fatigue in multiple sclerosis. ( Nathwani, S; Rowell, G; Spiwak, R; Tejani, AM; Wasdell, M, 2012) |
| "Fatigue affects more than 60% of multiple sclerosis (MS) patients and is one of the most troublesome symptoms of the disease." | 2.78 | Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. ( Ledinek, AH; Rot, U; Sajko, MC, 2013) |
| "Fatigue is frequently reported in hepatic encephalopathy (HE) and may be related to hyperammonemia." | 2.76 | Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. ( Bella, R; Galvano, F; Giordano, M; Li Volti, G; Malaguarnera, M; Pennisi, G; Rampello, L; Vacante, M, 2011) |
| "Ifosfamide and cisplatin cause urinary loss of carnitine, which is a fundamental molecule for energy production in mammalian cells." | 2.70 | Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. ( Baldelli, AM; Bisonni, R; Canestrari, F; Catalano, V; De Gaetano, A; Ferraro, B; Giordani, P; Graziano, F; Lai, V; Mencarini, E; Rovidati, S; Silva, R; Testa, E, 2002) |
| "Fatigue was assessed by the Functional Assessment of Cancer Therapy-Fatigue quality of life questionnaire." | 2.70 | Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. ( Baldelli, AM; Bisonni, R; Canestrari, F; Catalano, V; De Gaetano, A; Ferraro, B; Giordani, P; Graziano, F; Lai, V; Mencarini, E; Rovidati, S; Silva, R; Testa, E, 2002) |
| "Hepatic encephalopathy is a common and devastating neuropsychiatric complication of acute liver failure or chronic liver disease." | 2.61 | Acetyl-L-carnitine for patients with hepatic encephalopathy. ( Arevalo-Rodriguez, I; Gluud, C; Martí-Amarista, CE; Martí-Carvajal, AJ, 2019) |
| "Treatment for hepatic encephalopathy is complex." | 2.61 | Acetyl-L-carnitine for patients with hepatic encephalopathy. ( Arevalo-Rodriguez, I; Gluud, C; Martí-Amarista, CE; Martí-Carvajal, AJ, 2019) |
| "Hence, we have no data on the drug for hepatic encephalopathy in acute liver failure." | 2.61 | Acetyl-L-carnitine for patients with hepatic encephalopathy. ( Arevalo-Rodriguez, I; Gluud, C; Martí-Amarista, CE; Martí-Carvajal, AJ, 2019) |
| "Fatigue is reported to occur in up to 92% of patients with multiple sclerosis (MS) and has been described as the most debilitating of all MS symptoms by 28% to 40% of MS patients." | 2.48 | Carnitine for fatigue in multiple sclerosis. ( Nathwani, S; Rowell, G; Spiwak, R; Tejani, AM; Wasdell, M, 2012) |
| "Fatigue is reported to occur in up to 92% of patients with multiple sclerosis (MS) and has been described as the most debilitating of all MS symptoms by 28% to 40% of MS patients." | 2.46 | Carnitine for fatigue in multiple sclerosis. ( Nathwani, S; Rowell, G; Spiwak, R; Tejani, AM; Wasdell, M, 2010) |
| "Fatigue is an indispensable biosignal for maintaining life." | 2.42 | [Neural and molecular mechanisms of fatigue and recovery from fatigue]. ( Watanabe, Y, 2003) |
| "Fatigue is an indispensable sense for ordering rest." | 1.31 | Brain regions involved in fatigue sensation: reduced acetylcarnitine uptake into the brain. ( Evengård, B; Hagberg, G; Iwase, M; Kanakura, Y; Kitani, T; Kuratsune, H; Långström, B; Lindh, G; Machii, T; Matsumura, K; Onoe, H; Takahashi, M; Watanabe, Y; Yamaguti, K, 2002) |
| "Two patients with muscle phosphorylase deficiency [McArdle's disease (McA)] were studied during bicycle exercise at 40 (n = 2) and 60 W (n = 1)." | 1.28 | Impaired oxidative metabolism increases adenine nucleotide breakdown in McArdle's disease. ( Areskog, NH; Haller, RG; Henriksson, KG; Jorfeldt, L; Lewis, SF; Sahlin, K, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Naureen, Z | 1 |
| Dautaj, A | 1 |
| Nodari, S | 1 |
| Fioretti, F | 1 |
| Dhuli, K | 1 |
| Anpilogov, K | 1 |
| Lorusso, L | 1 |
| Paolacci, S | 1 |
| Michelini, S | 1 |
| Guda, T | 1 |
| Kallazi, M | 1 |
| Bertelli, M | 1 |
| Qutob, HMH | 1 |
| Saad, RA | 1 |
| Bali, H | 1 |
| Osailan, A | 1 |
| Jaber, J | 1 |
| Alzahrani, E | 1 |
| Alyami, J | 1 |
| Elsayed, H | 1 |
| Alserihi, R | 1 |
| Shaikhomar, OA | 1 |
| Divya, KM | 1 |
| Savitha, DP | 1 |
| Krishna, GA | 1 |
| Dhanya, TM | 1 |
| Mohanan, PV | 1 |
| Shah, SF | 1 |
| Jafry, AT | 1 |
| Hussain, G | 1 |
| Kazim, AH | 1 |
| Ali, M | 1 |
| Rivani, E | 1 |
| Endraswari, PD | 1 |
| Widodo, ADW | 1 |
| Khalil, MR | 1 |
| Guldberg, R | 1 |
| Nørgård, BM | 1 |
| Uldbjerg, N | 1 |
| Wehberg, S | 1 |
| Fowobaje, KR | 1 |
| Mashood, LO | 1 |
| Ekholuenetale, M | 1 |
| Ibidoja, OJ | 1 |
| Romagnoli, A | 1 |
| D'Agostino, M | 1 |
| Pavoni, E | 1 |
| Ardiccioni, C | 1 |
| Motta, S | 1 |
| Crippa, P | 1 |
| Biagetti, G | 1 |
| Notarstefano, V | 1 |
| Rexha, J | 1 |
| Perta, N | 1 |
| Barocci, S | 1 |
| Costabile, BK | 1 |
| Colasurdo, G | 1 |
| Caucci, S | 1 |
| Mencarelli, D | 1 |
| Turchetti, C | 1 |
| Farina, M | 1 |
| Pierantoni, L | 1 |
| La Teana, A | 1 |
| Al Hadi, R | 1 |
| Cicconardi, F | 1 |
| Chinappi, M | 1 |
| Trucchi, E | 1 |
| Mancia, F | 1 |
| Menzo, S | 1 |
| Morozzo Della Rocca, B | 1 |
| D'Annessa, I | 1 |
| Di Marino, D | 1 |
| Choya, A | 1 |
| de Rivas, B | 1 |
| Gutiérrez-Ortiz, JI | 1 |
| López-Fonseca, R | 1 |
| Xu, S | 1 |
| Cheng, B | 1 |
| Huang, Z | 1 |
| Liu, T | 1 |
| Li, Y | 1 |
| Jiang, L | 1 |
| Guo, W | 1 |
| Xiong, J | 1 |
| Amirazodi, M | 1 |
| Daryanoosh, F | 1 |
| Mehrabi, A | 1 |
| Gaeini, A | 1 |
| Koushkie Jahromi, M | 1 |
| Salesi, M | 1 |
| Zarifkar, AH | 1 |
| Studeny, P | 1 |
| Netukova, M | 1 |
| Nemcokova, M | 1 |
| Klimesova, YM | 1 |
| Krizova, D | 1 |
| Kang, H | 1 |
| Tao, Y | 1 |
| Zhang, Q | 1 |
| Sha, D | 1 |
| Chen, Y | 1 |
| Yao, J | 1 |
| Gao, Y | 1 |
| Liu, J | 1 |
| Ji, L | 1 |
| Shi, P | 1 |
| Shi, C | 1 |
| Wu, YL | 1 |
| Wright, AI | 1 |
| M El-Metwaly, N | 1 |
| A Katouah, H | 1 |
| El-Desouky, MG | 1 |
| El-Bindary, AA | 1 |
| El-Bindary, MA | 1 |
| Kostakis, ID | 1 |
| Raptis, DA | 1 |
| Davidson, BR | 1 |
| Iype, S | 1 |
| Nasralla, D | 1 |
| Imber, C | 1 |
| Sharma, D | 1 |
| Pissanou, T | 1 |
| Pollok, JM | 1 |
| Hughes, AM | 1 |
| Sanderson, E | 1 |
| Morris, T | 1 |
| Ayorech, Z | 1 |
| Tesli, M | 1 |
| Ask, H | 1 |
| Reichborn-Kjennerud, T | 1 |
| Andreassen, OA | 1 |
| Magnus, P | 1 |
| Helgeland, Ø | 1 |
| Johansson, S | 1 |
| Njølstad, P | 1 |
| Davey Smith, G | 1 |
| Havdahl, A | 1 |
| Howe, LD | 1 |
| Davies, NM | 1 |
| Amrillah, T | 1 |
| Prasetio, A | 1 |
| Supandi, AR | 1 |
| Sidiq, DH | 1 |
| Putra, FS | 1 |
| Nugroho, MA | 1 |
| Salsabilla, Z | 1 |
| Azmi, R | 1 |
| Grammatikopoulos, P | 1 |
| Bouloumis, T | 1 |
| Steinhauer, S | 1 |
| Mironov, VS | 2 |
| Bazhenova, TA | 2 |
| Manakin, YV | 2 |
| Yagubskii, EB | 2 |
| Yakushev, IA | 1 |
| Gilmutdinov, IF | 1 |
| Simonov, SV | 1 |
| Lan, K | 1 |
| Yang, H | 1 |
| Zheng, J | 1 |
| Hu, H | 1 |
| Zhu, T | 1 |
| Zou, X | 1 |
| Hu, B | 1 |
| Liu, H | 1 |
| Olokede, O | 1 |
| Wu, H | 1 |
| Holtzapple, M | 1 |
| Gungor, O | 1 |
| Kose, M | 1 |
| Ghaemi, R | 1 |
| Acker, M | 1 |
| Stosic, A | 1 |
| Jacobs, R | 1 |
| Selvaganapathy, PR | 1 |
| Ludwig, N | 1 |
| Yerneni, SS | 1 |
| Azambuja, JH | 1 |
| Pietrowska, M | 1 |
| Widłak, P | 1 |
| Hinck, CS | 1 |
| Głuszko, A | 1 |
| Szczepański, MJ | 1 |
| Kärmer, T | 1 |
| Kallinger, I | 1 |
| Schulz, D | 1 |
| Bauer, RJ | 1 |
| Spanier, G | 1 |
| Spoerl, S | 1 |
| Meier, JK | 1 |
| Ettl, T | 1 |
| Razzo, BM | 1 |
| Reichert, TE | 1 |
| Hinck, AP | 1 |
| Whiteside, TL | 1 |
| Wei, ZL | 1 |
| Juan, W | 1 |
| Tong, D | 1 |
| Juan, LX | 1 |
| Sa, LY | 1 |
| Jie, HFM | 1 |
| Xiao, G | 1 |
| Xiang, LG | 1 |
| Jie, HM | 1 |
| Xu, C | 1 |
| Yu, DN | 1 |
| Yao, ZX | 1 |
| Bigdeli, F | 1 |
| Gao, XM | 1 |
| Cheng, X | 1 |
| Li, JZ | 1 |
| Zhang, JW | 1 |
| Wang, W | 2 |
| Guan, ZJ | 1 |
| Bu, Y | 1 |
| Liu, KG | 1 |
| Morsali, A | 1 |
| Das, R | 1 |
| Paul, R | 1 |
| Parui, A | 1 |
| Shrotri, A | 1 |
| Atzori, C | 1 |
| Lomachenko, KA | 1 |
| Singh, AK | 1 |
| Mondal, J | 1 |
| Peter, SC | 1 |
| Florimbio, AR | 1 |
| Coughlin, LN | 1 |
| Bauermeister, JA | 1 |
| Young, SD | 1 |
| Zimmerman, MA | 1 |
| Walton, MA | 1 |
| Bonar, EE | 1 |
| Demir, D | 1 |
| Balci, AB | 1 |
| Kahraman, N | 1 |
| Sunbul, SA | 1 |
| Gucu, A | 1 |
| Seker, IB | 1 |
| Badem, S | 1 |
| Yuksel, A | 1 |
| Ozyazicioglu, AF | 1 |
| Goncu, MT | 1 |
| Zhang, H | 1 |
| Zhou, H | 1 |
| Deng, Z | 1 |
| Luo, L | 1 |
| Ong, SP | 1 |
| Wang, C | 1 |
| Xin, H | 1 |
| Whittingham, MS | 1 |
| Zhou, G | 1 |
| Maemura, R | 1 |
| Wakamatsu, M | 1 |
| Matsumoto, K | 1 |
| Sakaguchi, H | 1 |
| Yoshida, N | 1 |
| Hama, A | 1 |
| Yoshida, T | 1 |
| Miwata, S | 1 |
| Kitazawa, H | 1 |
| Narita, K | 1 |
| Kataoka, S | 1 |
| Ichikawa, D | 1 |
| Hamada, M | 1 |
| Taniguchi, R | 1 |
| Suzuki, K | 1 |
| Kawashima, N | 1 |
| Nishikawa, E | 1 |
| Narita, A | 1 |
| Okuno, Y | 1 |
| Nishio, N | 1 |
| Kato, K | 1 |
| Kojima, S | 1 |
| Morita, K | 1 |
| Muramatsu, H | 1 |
| Takahashi, Y | 1 |
| Yirgu, A | 1 |
| Mekonnen, Y | 1 |
| Eyado, A | 1 |
| Staropoli, A | 1 |
| Vinale, F | 1 |
| Zac, J | 1 |
| Zac, S | 1 |
| Pérez-Padilla, R | 1 |
| Remigio-Luna, A | 1 |
| Guzmán-Boulloud, N | 1 |
| Gochicoa-Rangel, L | 1 |
| Guzmán-Valderrábano, C | 1 |
| Thirión-Romero, I | 1 |
| Statsenko, ME | 1 |
| Turkina, SV | 1 |
| Barantsevich, ER | 1 |
| Karakulova, YV | 1 |
| Baranova, NS | 1 |
| Morzhukhina, MV | 1 |
| Wang, Q | 1 |
| Gu, Y | 1 |
| Chen, C | 1 |
| Qiao, L | 1 |
| Pan, F | 1 |
| Song, C | 1 |
| Canetto, SS | 1 |
| Entilli, L | 1 |
| Cerbo, I | 1 |
| Cipolletta, S | 1 |
| Wu, Y | 2 |
| Zhu, P | 1 |
| Jiang, Y | 1 |
| Zhang, X | 1 |
| Wang, Z | 1 |
| Xie, B | 1 |
| Song, T | 1 |
| Zhang, F | 1 |
| Luo, A | 1 |
| Li, S | 1 |
| Xiong, X | 1 |
| Han, J | 1 |
| Peng, X | 1 |
| Li, M | 1 |
| Huang, L | 1 |
| Chen, Q | 1 |
| Fang, W | 1 |
| Hou, Y | 1 |
| Zhu, Y | 1 |
| Ye, J | 1 |
| Liu, L | 1 |
| Islam, MR | 1 |
| Sanderson, P | 1 |
| Johansen, MP | 1 |
| Payne, TE | 1 |
| Naidu, R | 1 |
| Cao, J | 1 |
| Yang, J | 1 |
| Niu, X | 1 |
| Liu, X | 1 |
| Zhai, Y | 1 |
| Qiang, C | 1 |
| Niu, Y | 1 |
| Li, Z | 1 |
| Dong, N | 1 |
| Wen, B | 1 |
| Ouyang, Z | 1 |
| Zhang, Y | 1 |
| Li, J | 2 |
| Zhao, M | 1 |
| Zhao, J | 1 |
| Morici, P | 1 |
| Rizzato, C | 1 |
| Ghelardi, E | 1 |
| Rossolini, GM | 1 |
| Lupetti, A | 1 |
| Gözüküçük, R | 1 |
| Cakiroglu, B | 1 |
| He, X | 1 |
| Li, R | 1 |
| Zhao, D | 1 |
| Zhang, L | 1 |
| Ji, X | 1 |
| Fan, X | 1 |
| Chen, J | 1 |
| Wang, Y | 1 |
| Luo, Y | 1 |
| Zheng, D | 1 |
| Xie, L | 1 |
| Sun, S | 1 |
| Cai, Z | 1 |
| Liu, Q | 1 |
| Ma, K | 1 |
| Sun, X | 1 |
| Drinkwater, JJ | 1 |
| Davis, TME | 1 |
| Turner, AW | 1 |
| Davis, WA | 1 |
| Suzuki, Y | 1 |
| Mizuta, Y | 1 |
| Mikagi, A | 1 |
| Misawa-Suzuki, T | 1 |
| Tsuchido, Y | 1 |
| Sugaya, T | 1 |
| Hashimoto, T | 1 |
| Ema, K | 1 |
| Hayashita, T | 1 |
| Martí-Carvajal, AJ | 1 |
| Gluud, C | 1 |
| Arevalo-Rodriguez, I | 1 |
| Martí-Amarista, CE | 1 |
| Ledinek, AH | 1 |
| Sajko, MC | 1 |
| Rot, U | 1 |
| Tejani, AM | 2 |
| Wasdell, M | 2 |
| Spiwak, R | 2 |
| Rowell, G | 2 |
| Nathwani, S | 2 |
| Malaguarnera, M | 4 |
| Vacante, M | 2 |
| Giordano, M | 1 |
| Pennisi, G | 2 |
| Bella, R | 2 |
| Rampello, L | 1 |
| Li Volti, G | 1 |
| Galvano, F | 1 |
| Bertino, G | 1 |
| Neri, S | 1 |
| Gargante, MP | 1 |
| Motta, M | 1 |
| Lupo, L | 1 |
| Chisari, G | 1 |
| Bruno, CM | 1 |
| Kuratsune, H | 1 |
| Yamaguti, K | 1 |
| Lindh, G | 1 |
| Evengård, B | 1 |
| Hagberg, G | 1 |
| Matsumura, K | 1 |
| Iwase, M | 1 |
| Onoe, H | 1 |
| Takahashi, M | 1 |
| Machii, T | 1 |
| Kanakura, Y | 1 |
| Kitani, T | 1 |
| Långström, B | 1 |
| Watanabe, Y | 3 |
| Tomassini, V | 1 |
| Pozzilli, C | 1 |
| Onesti, E | 1 |
| Pasqualetti, P | 1 |
| Marinelli, F | 1 |
| Pisani, A | 1 |
| Fieschi, C | 1 |
| Lebrun, C | 1 |
| Alchaar, H | 1 |
| Candito, M | 1 |
| Bourg, V | 1 |
| Chatel, M | 1 |
| Graziano, F | 1 |
| Bisonni, R | 1 |
| Catalano, V | 1 |
| Silva, R | 1 |
| Rovidati, S | 1 |
| Mencarini, E | 1 |
| Ferraro, B | 1 |
| Canestrari, F | 1 |
| Baldelli, AM | 1 |
| De Gaetano, A | 1 |
| Giordani, P | 1 |
| Testa, E | 1 |
| Lai, V | 1 |
| Sahlin, K | 1 |
| Areskog, NH | 1 |
| Haller, RG | 1 |
| Henriksson, KG | 1 |
| Jorfeldt, L | 1 |
| Lewis, SF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Study, Randomized, Parallel Group Controlled, Testing the Effectiveness of a Behavioral Cognitive Therapy (BCT) vs Usual Local Practice on the Fatigue of Patients With Relapsing Remittent Multiple Sclerosis (RRMS)[NCT03758820] | 105 participants (Actual) | Interventional | 2017-05-31 | Completed | |||
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| ORAL ACETYL-L-CARNITINE THERAPY REDUCES FATIGUE IN HEPATIC ENCEPHALOPATHY[NCT01223742] | 0 participants | Interventional | 2002-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for acetylcarnitine and Lassitude
| Article | Year |
|---|---|
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter | 2022 |
Acetyl-L-carnitine for patients with hepatic encephalopathy.
Topics: Acetylcarnitine; Ammonia; Chelating Agents; Fatigue; Female; Hepatic Encephalopathy; Humans; Liver C | 2019 |
Carnitine for fatigue in multiple sclerosis.
Topics: Acetylcarnitine; Adult; Fatigue; Humans; Multiple Sclerosis; Randomized Controlled Trials as Topic; | 2010 |
Carnitine for fatigue in multiple sclerosis.
Topics: Acetylcarnitine; Adult; Fatigue; Humans; Multiple Sclerosis; Randomized Controlled Trials as Topic; | 2010 |
Carnitine for fatigue in multiple sclerosis.
Topics: Acetylcarnitine; Adult; Fatigue; Humans; Multiple Sclerosis; Randomized Controlled Trials as Topic; | 2010 |
Carnitine for fatigue in multiple sclerosis.
Topics: Acetylcarnitine; Adult; Fatigue; Humans; Multiple Sclerosis; Randomized Controlled Trials as Topic; | 2010 |
Carnitine for fatigue in multiple sclerosis.
Topics: Acetylcarnitine; Adult; Amantadine; Fatigue; Humans; Multiple Sclerosis; Randomized Controlled Trial | 2012 |
[Neural and molecular mechanisms of fatigue and recovery from fatigue].
Topics: Acetylcarnitine; Ascorbic Acid; Biopterins; Brain; Cytokines; Fatigue; Glutamic Acid; Humans; Nerve | 2003 |
[Molecular/neural mechanisms of fatigue and the way to overcome fatigue].
Topics: Acetylcarnitine; Animals; Brain; Fatigue; Fatigue Syndrome, Chronic; Glucose; Glutamic Acid; Humans; | 2007 |
7 trials available for acetylcarnitine and Lassitude
| Article | Year |
|---|---|
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter | 2022 |
Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study.
Topics: Acetylcarnitine; Adult; Amantadine; Benzhydryl Compounds; Drug Combinations; Fatigue; Female; Humans | 2013 |
Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.
Topics: Acetylcarnitine; Adult; Aged; Ammonia; Double-Blind Method; Fatigue; Female; Hepatic Encephalopathy; | 2011 |
The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin.
Topics: Acetylcarnitine; Adult; Dietary Supplements; Fatigue; Female; Hepatitis C, Chronic; Humans; Interfer | 2011 |
Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial.
Topics: Acetylcarnitine; Adult; Amantadine; Analgesics, Non-Narcotic; Analysis of Variance; Confidence Inter | 2004 |
Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue.
Topics: Acetylcarnitine; Adolescent; Adult; Cyclophosphamide; Fatigue; Female; Humans; Immunosuppressive Age | 2006 |
Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients.
Topics: Acetylcarnitine; Aged; Antineoplastic Agents; Carnitine; Cisplatin; Fatigue; Female; Humans; Ifosfam | 2002 |
3 other studies available for acetylcarnitine and Lassitude
| Article | Year |
|---|---|
Proposal of a food supplement for the management of post-COVID syndrome.
Topics: Acetylcarnitine; Adult; Aged; COVID-19; Dietary Supplements; Fatigue; Female; Gastrointestinal Disea | 2021 |
Brain regions involved in fatigue sensation: reduced acetylcarnitine uptake into the brain.
Topics: Acetylcarnitine; Adult; Animals; Brain; Brain Mapping; Cerebral Cortex; Disease Models, Animal; Fati | 2002 |
Impaired oxidative metabolism increases adenine nucleotide breakdown in McArdle's disease.
Topics: Acetylcarnitine; Adenine Nucleotides; Adenosine Triphosphate; Adult; Ammonia; Exercise; Fatigue; Fem | 1990 |